**Source:** MZ Toutiao (美妆头条) · **Date:** 2026-10-16 · **Category:** Brand / R&D *原文：引领医美从单一材料迈向系统延衰新阶段的，为什么是华熙生物？* On October 13 Huaxi Biotech (华熙生物) launched two injectable medical-aesthetic products at a Beijing event themed "renew the age". One is its self-developed Runzhi ECM Needle (润致ECM针); the other is JUVELOOK, a Korean product it now distributes in China. The company frames the move as a shift from single-material anti-aging to "systemic aging intervention" built around the extracellular matrix (ECM) — the microenvironment that surrounds cells and is seen as key to skin health and longevity. Runzhi ECM Needle won NMPA registration in August 2026 — a cross-linked sodium hyaluronate gel with glycine, proline and lysine — approved for moderate-to-severe static perioral wrinkles. JUVELOOK, developed by Korea's VAIM, pairs PDLLA microspheres with hyaluronic acid to rebuild the ECM across layers; it is already sold in more than 70 countries and cleared NMPA in July 2026, with Huaxi taking China distribution rights. The group raised ECM to company-wide strategy in October 2025 and says all future lines will be built around it. Detail --- Runzhi ECM Needle + JUVELOOK launch NMPA-

相关内容